Get In Touch

Osteoporosis is a progressive systemic skeletal disorder characterized by skeletal fragility, microarchitectural disruption, and low bone mass, resulting in decreased bone strength and an increased risk of fracture. Majority of post-menopausal osteoporosis occurs due to estrogen deficiency. Post-menopausal osteoporosis is a disease that ranges from asymptomatic bone loss to disabling hip fracture. Osteoporosis is a worldwide health issue because of the associated morbidity, mortality, and costs. The prevalence of the disease is not only in western countries but also in Latin America and Asia Pacific. According to World Health Organization, more than 75 million people suffer from osteoporosis fracture in Europe, Japan, and the U.S., and more than 2.3 million fractures occur annually alone in Europe and the U.S. Hip fracture is the most serious osteoporotic fracture, which results from falls, but some occur spontaneously. Women are highly affected than men, and there is an increasing incidence of the disease with age. The risk of hip fracture lies between 14% and 20% among women in the U.S. and Europe. In most cases, post-menopausal osteoporosis is a silent disease because no symptoms are seen until the fracture occurs. The combined risk for spine, hip, and forearm fracture has been estimated to be approximately 40%, which is similar to coronary artery disease. The risk of an osteoporotic fracture increases exponentially with age due to the decrease in bone density or bone mineral density (BMD) and the occurrence of other age-related accidents, e.g., increasing incidence of falls. 

Factors such as aging population, decline in estrogen levels after menopause, lifestyle changes such as smoking and alcohol consumption, and increase in bone loss after menopause are projected to drive the post-menopausal osteoporosis market globally. Mergers & acquisitions and new product innovation are another fueling factors which are expected to add value to the post-menopausal osteoporosis market. On other hand, high standards regulatory approval of any new product launch into the market, competition from the emerging alternative technologies, and intense competition from generics are estimated to hinder the growth of the market. 

The post-menopausal osteoporosis market has been segmented by treatment, distribution channel, and geography. In terms of treatment, the market is classified into vitamin D, bisphosphonates, calcitonin, hormone replacement therapy, estrogen antagonist, parathyroid hormone, and combination therapy. In terms of distribution channel, the market is classified into hospital pharmacies, retail pharmacies, and online pharmacies.

Geographically, the post-menopausal osteoporosis market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. 

Geographically, North America dominates the market due to growing number of geriatric population, and early adoption of treatment procedure, which in turn are likely to drive the post-menopausal osteoporosis market. The geriatric population represents about 14.5% of the U.S. population. According to U.S. Department of Health and Human Services by 2060, the number is expected to grow to 98 million, which is twice of 2014 geriatric population in the U.S. Europe is the second largest market due to increase in research and development activities as well as new product innovation. Asia Pacific is expected to grow at a higher rate due to rise in health care expenditure and research & development activities, along with development in medical tourism. Latin America and Middle East & Africa are projected to create large opportunities for the post-menopausal osteoporosis market owing to increase in health care insurance policies, growth in awareness among people, and shift of more number of companies toward these regions due to untapped markets. These factors are likely to add value to the Latin America and Middle East & Africa post-menopausal osteoporosis markets. 

Major players operating in this market include Amgen Inc., Clonz Biotech Pvt Ltd, Eli Lilly and Company, Enteris BioPharma, Inc., Ligand Pharmaceuticals, Inc., Merck & Co., Inc., Oncobiologics, Inc., Paras Biopharmaceuticals Finland Oy, BiologicsMD, Inc., and Radius Health, Inc. 

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Post Menopausal Osteoporosis Market